Literature DB >> 24051199

The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.

Wei Zhang1, Keqin Zhang, Lige Song, Jing Pang, Hongxing Ma, Eileen M Shore, Frederick S Kaplan, Peijun Wang.   

Abstract

Fibrodysplasia ossificans progressiva, an ultra-rare and disabling genetic disorder of skeletal malformations and progressive heterotopic ossification (HO), is the most catastrophic condition of skeletal metamorphosis in humans. We studied 72 patients with FOP in China and analyzed their phenotypes and genotypes comprising the world's largest ethnically homogeneous population of FOP patients. Ninety-nine percent of patients (71/72 cases) were of Han nationality; and 1% of patients (1/72 cases) were of Hui nationality. Based on clinical examination, 92% of patients (66/72 cases) had classic FOP; 4% of patients (3/72 cases) were FOP-plus; and 4% of patients (3/72) were FOP variants. Importantly, all individuals with FOP had mutations in the protein-coding region of activin A receptor, type I/activin-like kinase 2 (ACVR1/ALK2). Ninety-seven percent of FOP patients (70/72 cases) had the canonical c.617G>A (p.R206H) mutation, while 3% of FOP patients (2/72 cases) had variant mutations in ACVR1/ALK2. Taken together, the genotypes and phenotypes of individuals with FOP from the Han nationality in China are similar to those reported elsewhere and support the fidelity of this ultra-rare disorder in the world's most highly populated nation and across wide racial, ethnic, gender and geographic distributions.
© 2013.

Entities:  

Keywords:  ACVR1; ALK2; Bone morphogenetic protein; Fibrodysplasia ossificans progressiva; Heterotopic ossification

Mesh:

Year:  2013        PMID: 24051199      PMCID: PMC3975922          DOI: 10.1016/j.bone.2013.09.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  31 in total

1.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Fibrodysplasia ossificans progressiva.

Authors:  S Mahboubi; D L Glaser; E M Shore; F S Kaplan
Journal:  Pediatr Radiol       Date:  2001-05

Review 3.  Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.

Authors:  Frederick S Kaplan; Vitali Y Lounev; Haitao Wang; Robert J Pignolo; Eileen M Shore
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

4.  A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H).

Authors:  Hirokazu Furuya; Koji Ikezoe; Lixiang Wang; Yasumasa Ohyagi; Kyoko Motomura; Naoki Fujii; Jun-Ichi Kira; Yasuyuki Fukumaki
Journal:  Am J Med Genet A       Date:  2008-02-15       Impact factor: 2.802

5.  Mutation Analysis and Prenatal Exclusion of Fibrodysplasia Ossificans Progressiva in a Chinese Fetus.

Authors:  Juan Du; Ling-Li Huang; Yue-Qiu Tan; De-Hua Cheng; Shuang-Fei Li; Lu-Yun Li; Guang-Xiu Lu
Journal:  Genet Test Mol Biomarkers       Date:  2010-01-10

6.  Confirmation of the recurrent ACVR1 617G>A mutation in South Africans with fibrodysplasia ossificans progressiva.

Authors:  Collet Dandara; Chris Scott; Mike Urban; Karen Fieggen; Regan Arendse; Peter Beighton
Journal:  S Afr Med J       Date:  2012-05-08

7.  Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

Authors:  Toru Fukuda; Masakazu Kohda; Kazuhiro Kanomata; Junya Nojima; Atsushi Nakamura; Jyunji Kamizono; Yasuo Noguchi; Kiyofumi Iwakiri; Takeo Kondo; Junichi Kurose; Ken-ichi Endo; Takeshi Awakura; Junichi Fukushi; Yasuharu Nakashima; Tomohiro Chiyonobu; Akira Kawara; Yoshihiro Nishida; Ikuo Wada; Masumi Akita; Tetsuo Komori; Konosuke Nakayama; Akira Nanba; Yuichi Maruki; Tetsuya Yoda; Hiroshi Tomoda; Paul B Yu; Eileen M Shore; Frederick S Kaplan; Kohei Miyazono; Masaru Matsuoka; Kenji Ikebuchi; Akira Ohtake; Hiromi Oda; Eijiro Jimi; Ichiro Owan; Yasushi Okazaki; Takenobu Katagiri
Journal:  J Biol Chem       Date:  2008-08-06       Impact factor: 5.157

Review 8.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

9.  Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects.

Authors:  A Morales-Piga; J Bachiller-Corral; M J Trujillo-Tiebas; A Villaverde-Hueso; M L Gamir-Gamir; V Alonso-Ferreira; M Vázquez-Díaz; M Posada de la Paz; C Ayuso-García
Journal:  Bone       Date:  2012-07-13       Impact factor: 4.398

10.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

View more
  17 in total

1.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

Review 2.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 3.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

4.  Clinical and molecular characterisation of two siblings with fibrodysplasia ossificans progressiva, from the Colombian Pacific coast (South America).

Authors:  Harry Pachajoa; Andres Felipe Ramirez Botero
Journal:  BMJ Case Rep       Date:  2015-06-08

5.  Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Authors:  Frederick S Kaplan; Joyce A Kobori; Carmen Orellana; Inmaculada Calvo; Monica Rosello; Francisco Martinez; Berta Lopez; Meiqi Xu; Robert J Pignolo; Eileen M Shore; Jay C Groppe
Journal:  Am J Med Genet A       Date:  2015-06-11       Impact factor: 2.802

6.  Fibrodysplasia ossificans progressiva: Diagnosis with ultrasound.

Authors:  Lino Piotto; Ajay Taranath
Journal:  Australas J Ultrasound Med       Date:  2021-05-05

7.  Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China.

Authors:  Jun-Mei Zhang; Cai-Feng Li; Shuang-Ying Ke; Yu-Rong Piao; Tong-Xin Han; Wei-Ying Kuang; Jiang Wang; Jiang-Hong Deng; Xiao-Hua Tan; Chao Li
Journal:  World J Pediatr       Date:  2019-09-16       Impact factor: 2.764

Review 8.  The biological function of type I receptors of bone morphogenetic protein in bone.

Authors:  Shuxian Lin; Kathy K H Svoboda; Jian Q Feng; Xinquan Jiang
Journal:  Bone Res       Date:  2016-04-05       Impact factor: 13.567

Review 9.  The revolution in human monogenic disease mapping.

Authors:  Emma Duncan; Matthew Brown; Eileen M Shore
Journal:  Genes (Basel)       Date:  2014-09-05       Impact factor: 4.096

10.  Difficult diagnosis and genetic analysis of fibrodysplasia ossificans progressiva: a case report.

Authors:  Shengjie Tian; Jianhua Zhu; Yaogang Lu
Journal:  BMC Med Genet       Date:  2018-02-27       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.